21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer

@article{Turashvili201721GeneRS,
  title={21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer},
  author={G. Turashvili and J. Chou and E. Brogi and M. Morrow and M. Dickler and L. Norton and C. Hudis and H. Wen},
  journal={Breast Cancer Research and Treatment},
  year={2017},
  volume={166},
  pages={69-76}
}
Background/purposeThe 21-gene recurrence score (RS) assay evaluates the likelihood of distant recurrence and benefit of chemotherapy in lymph node-negative, estrogen receptor (ER)-positive, HER2-negative breast cancer patients. The RS categories are associated with the risk of locoregional recurrence (LRR) in some, but not all studies.MethodsWe reviewed the institutional database to identify consecutive female patients with node-negative, ER+/HER2− breast carcinoma tested for the 21-gene RS… Expand
Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up
TLDR
This study of node negative, ER+/HER2- breast cancer patients with low RS observed extremely low rates of LRR: 0.9% in the whole cohort and 0.7% in patients treated with endocrine therapy alone. Expand
Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer
Background Although the 21-gene recurrence score (RS) assay is widely used to predict distant recurrence risk and benefit from adjuvant chemotherapy among women with hormone receptor-positive (HR+)Expand
Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases
TLDR
The 21-gene RS does predict outcome and impact on chemotherapy decision of N1mi breast IDC and there were similar trends using Trial Assigning Individualized Options for Treatment RS cutoffs. Expand
Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage.
TLDR
Tumor size and histological grade were independent variables, predicting high risk in patients with hormone receptor-positive, node-negative breast cancer; 21-gene RS assessment was potentially a critical tool in guiding adjuvant decision-making in China. Expand
The 21-Gene Recurrence Score in Male Breast Cancer
TLDR
The results suggest that the RS may have a clinical utility in male breast cancer patients, and with limited follow-up, patients with low RS were spared chemotherapy and did not develop recurrence. Expand
Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis
  • Yujie Lu, Yiwei Tong, +5 authors Kunwei Shen
  • Medicine
  • Cancer management and research
  • 2021
Background It remains uncertain whether the 21-gene recurrence score (RS) of a primary tumor has selective prognostic value for locoregional recurrence (LRR) or distant metastasis (DM). The currentExpand
Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer
TLDR
LVI adds prognostic information in ER+, HER2−, N0 BCA with RS 11–100, but does not predict chemotherapy benefit, and Black race is associated with worse OS, but not LVI. Expand
Impact of Oncotype DX Recurrence Score on the Patterns of Locoregional Recurrence in Breast Cancer (Korean Radiation Oncology Group 19-06)
  • Kyubo Kim, Jinhong Jung, +7 authors Jee Suk Chang
  • Medicine
  • Journal of breast cancer
  • 2020
TLDR
The current study evaluated the impact of the Oncotype DX recurrence score on the patterns of locoregional recurrence (LRR) in node-negative, hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, finding that RNI might be effective for patients with a high RS. Expand
OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients
TLDR
OncotypeDXRS is not associated with nodal burden in women with clinically node-negative breast cancer, suggesting that RS is not useful to guide decisions regarding extent of axillary surgery for these patients. Expand
Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer
TLDR
This study provides additional support for a shared decision-making process for BCS when both local management options are appropriate choices regardless of the 21-gene RS, and indicates that patients with high-risk RS were more likely to receive MAST. Expand
...
1
2
...

References

SHOWING 1-10 OF 38 REFERENCES
The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients
TLDR
Breast cancer patients treated with mastectomy for tumors that have an RS > 24 are at high risk of LRR and may benefit from post-mastectomy radiation, and patients who receive BCT was not associated with LRR in patients who received BCT. Expand
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
  • E. Mamounas, G. Tang, +7 authors N. Wolmark
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
A significant association exists between RS and risk for locoregional recurrence (LRR) in patients with node-negative, ER-positive breast cancer from two National Surgical Adjuvant Breast and Bowel Project trials and in multivariate analysis, RS was an independent significant predictor of LRR along with age and type of initial treatment. Expand
Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer
TLDR
RS use is increasing, and the assay significantly reduced adjuvant chemotherapy utilization in node-negative, ER -positive breast cancer patients, according to guidelines from NCCN, St. Gallen, and Adjuvant. Expand
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
TLDR
Overall, IBTR! did not correlate with RS, and further study is warranted to determine if the RS can provide complementary biological information to CP factors in estimating the risk of LR. Expand
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
  • S. Paik, G. Tang, +11 authors N. Wolmark
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit. Expand
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
TLDR
RS-guided chemotherapy decision-making resulted in a substantial modification of adjuvant chemotherapy usage in node-negative and node-positive ER+ EBC and was cost-saving versus current clinical practice. Expand
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
TLDR
The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients. Expand
The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.
TLDR
The 21-gene assay, when applied in a consistent manner in early-stage BC, changes treatment recommendations in one-quarter of patients tested, and correlated poorly with AO predictions. Expand
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
TLDR
Results from the first prospective European study are consistent with published experience and use of the RS and provide evidence on how Oncotype DX and clinicopathological factors are complementary and patient selection may be improved. Expand
Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
TLDR
The RS substantially influenced both oncologists' recommendations and patients' preferences for chemotherapy, and the major effect was avoidance of chemotherapy when AOL indicated high or intermediate risk. Expand
...
1
2
3
4
...